Alzheimer's Disease and mild cognitive impairment

被引：233

作者：

Kelley, Brendan J. ^{[1
]}

Petersen, Ronald C. ^{[1
]}

机构：

[1] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA

来源：

NEUROLOGIC CLINICS | 2007年 / 25卷 / 03期

关键词：

D O I：

10.1016/j.ncl.2007.03.008

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

As our society ages, age-related diseases assume increasing prominence as both personal and public health concerns. Disorders of cognition are particularly important in both regards, and Alzheimer's disease is by far the most common cause of dementia of aging. In 2000, the prevalence of Alzheimer's disease in the United States was estimated to be 4.5 million individuals, and this number has been projected to increase to 14 million by 2050. Although not an inevitable consequence of aging, these numbers speak to the dramatic scope of its impact. This article focuses on Alzheimer's disease and the milder degrees of cognitive impairment that may precede the clinical diagnosis of probable Alzheimer's disease, such as mild cognitive impairment.

引用

页码：577 / +

页数：34

共 202 条

[1]

ADAMIAK B, 2006, ALZHEIMERS DEMENT S1, V2, pS62

[2] Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].

Aisen, PS ;

Schafer, KA ;

Grundman, M ;

Pfeiffer, E ;

Sano, M ;

Davis, KL ;

Farlow, MR ;

Jin, S ;

Thomas, RG ;

Thal, LJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826

[3] A randomized controlled trial of prednisone in Alzheimer's disease [J].

Aisen, PS ;

Davis, KL ;

Berg, JD ;

Schafer, K ;

Campbell, K ;

Thomas, RG ;

Weiner, MF ;

Farlow, MR ;

Sano, M ;

Grundman, M ;

Thal, LJ .

NEUROLOGY, 2000, 54 (03) :588-593

[4]

AISEN PS, 1994, AM J PSYCHIAT, V151, P1105

[5] DO NONSTEROIDAL ANTIINFLAMMATORY DRUGS DECREASE THE RISK FOR ALZHEIMERS-DISEASE - THE ROTTERDAM STUDY [J].

ANDERSEN, K ;

LAUNER, LJ ;

OTT, A ;

HOES, AW ;

BRETELER, MMB ;

HOFMAN, A .

NEUROLOGY, 1995, 45 (08) :1441-1445

[6] Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897 [J].

Anderson, JJ ;

Holtz, G ;

Baskin, PP ;

Turner, M ;

Rowe, B ;

Wang, BW ;

Kounnas, MZ ;

Lamb, BT ;

Barten, D ;

Felsenstein, K ;

McDonald, I ;

Srinivasan, K ;

Munoz, B ;

Wagner, SL .

BIOCHEMICAL PHARMACOLOGY, 2005, 69 (04) :689-698

[7] Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample [J].

Andreasen, N ;

Minthon, L ;

Clarberg, A ;

Davidsson, P ;

Gottfries, J ;

Vanmechelen, E ;

Vanderstichele, H ;

Winblad, B ;

Blennow, K .

NEUROLOGY, 1999, 53 (07) :1488-1494

[8] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].

Andreasen, N ;

Hesse, C ;

Davidsson, P ;

Minthon, L ;

Wallin, A ;

Winblad, B ;

Vanderstichele, H ;

Vanmechelen, E ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680

[9]

[Anonymous], 1997, Neurobiol Aging, V18, pS1

[10]

[Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th

← 1 2 3 4 5 6 7 8 9 10 →